ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Clinical Trial Search Results

Displaying 243 Trials
Trial ID 18194
Sponsor ID STRO-002-GM1

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRá) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID 19239
Sponsor ID CX-839-014 "KEAPSAKE"

CX-839-014 “KEAPSAKE”: A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID 20186
Sponsor ID BO41932

TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)

Trial ID US-60010-001 NAPOLI3
Sponsor ID US-60010-001 NAPOLI3

An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic

Principal Investigator
Keeran R. Sampat, MD
Trial ID 20286
Sponsor ID SGN00-002

Screening protocol to detect HER2 alterations required for enrollment on clinical research protocols of tucatinib (SGN00-002)

Principal Investigator
Keeran R. Sampat, MD
5 Locations
Trial ID 20249
Sponsor ID 61186372NSC3001

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Principal Investigator
Alexander I Spira, MD, PhD, FACP
5 Locations
Trial ID CLN-081-001
Sponsor ID CLN-081-001

A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID 20189
Sponsor ID Incyte/ IQVIA

A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Principal Investigator
Ajay Dar, MD
Trial ID 20284
Sponsor ID Seattle Genetics, Inc.

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-025)

Principal Investigator
Anne Favret, MD
1 Location